Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
Grifols Announces New Needle-Free Factor Mixing Device
 

Grifols USA recently announced the availability of the Mix2Vial™ filter transfer set for the reconstitution and administration of Grifols’ coagulation therapies. The set is a plastic, needle-free transfer device with a built-in 15-micron filter designed to be used with the Sterile Water for Injection diluent packaged with Grifols’ coagulation products.

 

“We continually strive to meet our customer's needs and enhance the convenience and ease of using our medicines,” said Bill Stopher, President of Grifols USA. “Introduction of the Mix2Vial transfer set represents just one more step we can take to address the challenges of living with hemophilia.”

 

The Mix2Vial transfer sets will become available as the new device is phased in over several months. “DemoPacks” are available for instructional purposes so that patients, parents and nurses can become familiar with the new system.

 

Grifols manufactures several bleeding disorder therapies:

 

  • Alphanate® is a factor VIII/von Willebrand factor, plasma-derived product for the prevention and control of bleeding in patients with hemophilia A or acquired factor VIII deficiency. It is also indicated for surgical and/or invasive procedures in patients with von Willebrand disease (VWD) in whom desmopressin (DDAVP) is either ineffective or contraindicated. It is not indicated for patients with severe type 3 VWD undergoing major surgery.

  • AlphaNine®SD is a factor IX, plasma-derived product for the prevention and control of bleeding in patients with hemophilia B.

  • Profilnine®SD, a plasma-derived product containing factors IX, II, X and low levels of factor VII, is indicated for the prevention and control of bleeding in patients with hemophilia B.

Source: Grifols new release dated April 23, 2010